What Vasudha Pharma Chem does

Vasudha Pharma Chem Limited (CIN: U24230TG1994PLC019021) is a Hyderabad-headquartered, publicly listed Indian pharmaceutical manufacturer incorporated in 1994 under the Companies Act, 1956. The company manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and API pellets across five manufacturing units in Hyderabad and Visakhapatnam, plus the acquired Shri Ram Chloro Chem Private Limited facility in Sangareddy, with combined reactor capacity exceeding 1,700 KL. Since 2003-04 it has held the position of world's largest manufacturer of piperidone and piperidine derivatives, the key building blocks for several APIs in its portfolio of 40+ molecules spanning antidepressants, antihistamines, antihypertensives, antiulcerants, anticoagulants, and anti-inflammatory therapeutic categories. A dedicated pellets facility (Unit-IV) produces enteric-coated, sustained-release, immediate-release, and dual-delayed-release pellets, representing forward integration into semi-finished formulations, while a 12-API pipeline targets expansion into diabetes, migraine, and cardiovascular adjacencies.

The company serves global pharmaceutical MNCs across 90 countries through a direct B2B sales model, with approximately 40% of sales exported. Its manufacturing footprint is accredited by USFDA, WHO-GMP, KFDA, PMDA Japan, EDQM, ANVISA, and COFEPRIS, and it maintains Drug Master File filings with US, European, Japanese, Chinese, Korean, and Canadian regulatory authorities, positioning it as a preferred supplier into regulated generic markets. Revenue scaled from INR 0.02 billion in FY1997-98 to INR 10,772 million (~US$142M) in FY2020-21. Backed by a DSIR-approved R&D center with approximately 150 scientists, the company carries an IND A+/Stable credit rating from India Ratings (Fitch Group) and operates with family-controlled governance under founder-Chairman M.V. Rama Raju; in March 2026 it resolved prior U.S. Department of Justice proceedings via a Non-Prosecution Agreement, allowing a return to normal operations.

Name

Vasudha Pharma Chem

Legal name

Vasudha Pharma Chem Limited

Website

https://vasudhapharma.com

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Vasudha Pharma Chem Limited is a Hyderabad-based Indian pharmaceutical manufacturer producing APIs, intermediates, and pellets across six facilities, supplying global pharmaceutical MNCs in 90 countries and holding the position of world's largest piperidone and piperidine derivatives producer.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Api manufacturing
• Pharmaceutical pellets
• Organic synthesis chemistry

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of ~40+ APIs across multiple therapeutic areas including antidepressants, antihistamines, anti-ulcer, anti-thrombotic, anti-hypertensive, antipsychotics, and more. APIs include Amitriptyline HCl, Aripiprazole, Clopidogrel Bisulphate, Cyclobenzaprine HCl, Domperidone, Fexofenadine HCl, Losartan Potassium, Olmesartan Medoxomil, Pantoprazole Sodium, Telmisartan, and others. Export sales comprise approximately 40% of gross sales.
2. Pharma Intermediates: Backward integrated manufacturing of pharmaceutical intermediates, particularly piperidone and piperidine derivatives. Company is the largest manufacturer of piperidone and piperidine derivatives globally.
3. API Pellets (Semi-finished Formulations): Forward integrated Pellets manufacturing facility producing Enteric Coated, Enteric Release, Immediate Release, Sustain Release, and Dual Delayed Release pellets and MUPS & DC granules.
4. Drug Master File (DMF) Filing Services: Filed DMFs for various APIs with American, European, Japanese, Chinese, Korean, and Canadian regulatory authorities. Company serves as prime source of starting materials for various MNCs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Vasudha Pharma Chem Limited manufactures and sells Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and pellet formulations (MUPS & DC Granules) from five manufacturing facilities in India. It is the world's largest manufacturer of piperidone and piperidine derivatives and supplies a portfolio of 40+ APIs across multiple therapeutic areas to global pharmaceutical companies and MNCs.

Product overview

Vasudha Pharma Chem Limited operates as a vertically integrated pharmaceutical manufacturer offering a comprehensive product portfolio across the drug development value chain. The core offering consists of specialized Piperidone & Piperidine Derivatives (established as the world's largest manufacturer since 2003-04), pharmaceutical intermediates used as building blocks for APIs, and a portfolio of 40+ Active Pharmaceutical Ingredients (APIs) spanning therapeutic areas including antihistamines, antidepressants, antihypertensives, antiulcerants, anticoagulants, and anti-inflammatory drugs. The company has forward-integrated into API Pellets (MUPS & DC Granules) manufactured at a dedicated pellets facility, offering multiple release mechanisms including Enteric Coated, Enteric Release, Immediate Release, Sustained Release, and Dual Delayed Release formulations. A pipeline of 12 Under Development APIs targets conditions such as high cholesterol, diabetes, migraine prevention, and hypertension. The company operates five manufacturing facilities across India with regulatory approvals from USFDA, WHO-GMP, KFDA, PMDA Japan, EDQM, ANVISA, and COFEPRIS.

Differentiator

Problem solved

Functional benefit

Brands

• Vasudha Foundation: Social service organization providing education, health, shelter, rehabilitation and environmental sustainability programs

Products and services

• Active Pharmaceutical Ingredients (APIs)

Quantifiable outcome

• Revenue growth from INR 0.0164 billion (US$ 0.25 million) in FY 1997-98 to INR 10,772 billion (US$ 142 million) in FY 2020-2021
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators10 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Divi's Laboratories: Leading Indian manufacturer of active pharmaceutical ingredients and intermediates, with strong custom synthesis and a globally recognized API/intermediates franchise. Highly comparable to Vasudha on intermediates-to-API model and export orientation to regulated markets.
• Laurus Labs: Indian API and intermediates manufacturer with strong exposure to ARV, cardiovascular and CNS molecules and significant U.S./Europe regulated-market presence. Closely comparable on small-molecule API focus, DMF-led strategy, and export-led revenue mix.
• MSN Laboratories: Hyderabad-based Indian API and finished formulation manufacturer with strong R&D, custom synthesis capabilities, and global regulatory filings. Highly comparable on geographic base, therapeutic focus, and B2B API supply model.
• Granules India: Indian manufacturer of APIs, pharmaceutical formulation intermediates (PFIs), and finished dosages with a strong pellets and DC-grade franchise. Direct overlap with Vasudha's pellets and intermediates strategy and global B2B distribution.
• Hetero Labs: Indian API and finished formulation manufacturer with deep presence in ARVs and a globally diversified portfolio. Comparable as a Hyderabad-headquartered private-leaning API player serving regulated and emerging markets.

Broad incumbents

• Aurobindo Pharma: One of India's largest generic API and finished dosage manufacturers with broad therapeutic coverage and USFDA-inspected infrastructure. Comparable in API manufacturing capabilities, though much larger and vertically integrated into finished formulations.
• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with integrated API-to-formulation operations, strong U.S./Europe presence, and an active proprietary products business. Overlaps with Vasudha on API manufacturing and DMF filings, though far larger and branded.
• Sun Pharmaceutical Industries: India's largest specialty generics company with significant API manufacturing footprint. Comparable on small-molecule API production and global regulatory approvals, but operates at significantly greater scale with branded generics and specialty franchises.
• Cipla: Major Indian pharmaceutical manufacturer with global API and finished dosage operations. Comparable on the API manufacturing and regulated-market supply dimensions, though predominantly finished-formulation focused.

Emerging players

• Sequent Scientific: Indian manufacturer focused on animal health APIs and formulations with some human API exposure. A smaller-scale peer showing the API-manufacturing-plus-international-registrations model Vasudha operates, albeit in a different end market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/VasudhaPharma678
• LinkedInlinkedin.com/company/vasudha-pharma-chem-ltd-

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vasudha Pharma Chem